SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMDs stronger-than-expected quarterly results and upbeat next-quarter outlook, supported by surging data-center and AI demand, sparked a rally and renewed optimism in semiconductors. Traders welcomed the results as evidence the AI trade remains strong, while others questioned the valuation and cash-flow outlook and warned of a possible sell-the-news reversal.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micros strong quarterly results and raised sales outlook, attributed to robust AI-server demand, are driving attention. Bulls call the report a major beat and see the shares as undervalued, while others question the muted price reaction and point to margin pressure, negative operating cash flow, inventory growth, and lingering concerns about management credibility.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Midterm-election uncertainty is driving attention to DJT, with traders linking the shares move to expectations around the vote and debating whether Democratic gains would pressure the Trump-linked stock or a Republican showing could support it. Discussion is sharply divided, while the TAE Technologies merger and possible short covering appear as secondary themes.

Arista Networks, Inc. engages in the development, marketing, and sale of cloud networking solutions. Its solutions include EOS, a set of network applications, and Gigabit Ethernet switching and routing platforms. Its product categories include core, cognitive adjacencies, and cognitive networks. The company was founded by Andreas Bechtolsheim, David Cheriton, and Kenneth Duda in November 2004 and is headquartered in Santa Clara, CA.

Arista Networks Inc

Aristas quarterly results beat expectations and its forward outlook exceeded forecasts, driving a positive reaction. Traders view the results as support for AI data-center networking demand, though some remain wary of volatile post-earnings swings.

Astera Labs, Inc. provides rack-scale AI infrastructure through purpose-built connectivity solutions. The company offers a range of semiconductor-based connectivity solutions designed to address bandwidth, latency, and reliability challenges in AI and cloud data centers. The company was founded by Jitendra Mohan, Casey Morrison, and Sanjay Gajendra in October 2017 and headquartered in San Jose, CA.

Astera Labs Inc.

Astera Labs Inc

Astera Labs quarterly results beat expectations and its forward guidance came in stronger than anticipated, but the stocks volatile post-earnings reaction has fueled debate. Bulls point to accelerating AI-infrastructure demand, while skeptics argue the growth is already reflected in a premium valuation.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Trading is focused on the FDAs pending decision on Capricors deramiocel therapy for Duchenne muscular dystrophy, with traders debating the chances of approval and anticipating a possible short-covering run-up. Many are bullish on the upper-limb data and physician support, while others point to FDA advisory-panel concerns and the risk of a rejection; some also attribute recent strength to short covering or spillover from another biotech approval.

Cipher Digital, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Digital Inc.

Cipher Digital is rebounding after a steep selloff, with traders pointing to a broader rally in AI-infrastructure and mining stocks and speculating about oversold conditions or short covering. The bullish reaction also draws on analyst support and the companys early HPC leasing progress, while skeptics view the move as a temporary bounce after a revenue miss and ongoing execution and financing concerns.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

AMDs strong earnings and data-center outlook are dominating discussion, with traders treating the results as a read-through for AI-chip demand and a possible lift for Nvidia and the broader semiconductor sector. Bulls say the report supports continued AI spending, while bears point to NVDAs recent weakness, valuation and financing concerns, and election-related uncertainty.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas drew attention with quarterly results ahead of expectations and a stronger outlook, alongside its NVIDIA collaboration on an 800V AI data-center power board. Bulls see the results and AI-power opportunity as evidence of a growth pivot, while skeptics argue that design work has yet to translate into meaningful customer orders and revenue.

Ouster, Inc. engages in the provision of high resolution digital lidar sensors that offer advanced 3D vision to machinery, vehicles, robots, and fixed infrastructure assets. The company was founded by Angus Pacala and Mark Frichtl on June 30, 2015 and is headquartered in San Francisco, CA.

Ouster Inc - Ordinary Shares - Class A

Ousters third-quarter results are driving attention, with traders highlighting a revenue and EPS beat and continued growth, while debating whether ongoing losses and cash burn outweigh the operating progress. Reactions are mixed, with some buying the dip and others citing weak price action and broader pressure on growth stocks.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Earnings Preview: Moderna (MRNA) Q3 Earnings Expected to Decline

Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Alector (ALEC) Report Negative Q3 Earnings? What You Should Know

Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

High-Stakes Corporate Stories Putting Strategic Moves in the Spotlight

Today's corporate developments highlight some very different investment narratives: NeOnc Technologies Holdings (NASDAQ:NTHI) is pursuing new avenues for experimental brain-cancer treatments, Alector (NASDAQ:ALEC) is raising fresh capital for neurological disease research, Alaunos Therapeutics (NASDAQ:TCRT) is repositioning around pulmonary hypertension through a major acquisition, Zenta Group (NASDAQ:ZTG) is pursuing an artificial intelligence and data-services strategy, and Exascale Labs (NASDAQ:XLAB) is seeking to convert surging AI-computing demand into commercial growth.

Alector Raises $75 Million in Premium-Priced Stock Offering as Big Biotech Investors Back Fight Against Brain Disease

Alector (NASDAQ:ALEC) is putting $75 million on the table in a major financing move that could help fuel its next chapter in the race to develop treatments for Alzheimer’s, Parkinson’s and other devastating neurological disorders. The South San Francisco biotech priced an underwritten offering of 36.6 million common shares at $2.05 apiece, approximately 7.3% above its October 15 closing price.

Stocktwits Biotech Dealmaker — Viatris And GE Healthcare Buy What They Can Sell; Biohaven And Alector Sell Rights

Equity

Drugmakers this week did not purchase experimental drug candidates but invested in approved drugs and a factory that makes imaging agents. 


Biotech Junior Gains 21% as US$100M Upfront Pharma Deal Extends Cash Runway

Securing upfront cash equal to roughly half of its market value sent a small neuroscience developer sharply higher Monday, a reminder of how much a big pharma license can say about a preclinical delivery platform. Alector Inc. (NASDAQ: ALEC) rallied after signing an exclusive global license agreement with Genentech, a member of the Roche Group, for AL050, its brain-penetrant engineered glucocerebrosidase (GCase) enzyme replacement therapy. Alector will receive US$100M upfront and is eligible for up to US$1.17B in development, regulatory and commercial milestone payments, plus tiered ...

Brainiacs, Space Men, and Digital Assets

This week’s action puts Alector (NASDAQ:ALEC), NeOnc Technologies (NASDAQ:NTHI), WISeQey (NASDAQ:WKEY), Veea (NASDAQ:VEEA), and Stablecoin Development Corporation (NYSEAMERICAN:SDEV) squarely in that conversation.

Alector Lands $1.27 Billion Genentech Deal, as Brain-Delivery Platform Gets a Major Validation

Alector (NASDAQ:ALEC) just transformed one of its most important neuroscience programs into a potentially billion-dollar commercial opportunity.

12 Health Care Stocks Moving In Tuesday's After-Market Session

Gainers

Alector (NASDAQ:ALEC) shares increased by 9.7% to $2.59 during Tuesday's after-market session. The company's market cap stands at $256.8 million.
NeuroSense Therapeutics (NASDAQ:NRSN) shares increasedread more...

Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.

Alector Inc

Bearish Sentiment

<ul class="summary-bullets"><li><a class="mention" data-mention="$VTRS" data-symbol-id="VTRS" href="https://stocktwits.com/symbol/VTRS" target="_blank">Viatris</a> agreed on Thursday to buy Pacira BioSciences for $1.65 billion in cash, or $36.50 a share.</li><li>GE HealthCare agreed to pay $945 million in cash for Sofie Biosciences, a private U.S. firm that makes radioactive tracers for PET scans.</li><li>Biohaven licensed Asian rights to its antibody-clearing drugs to Japan’s Ono Pharmaceutical; Alector signed a separate license with Genentech.</li></ul><p>U.S.-listed drugmakers spent the week selling rights or buying products they can already sell. Cash went to approved pain drugs, a factory that makes imaging agents, and two license deals, including one that leaves the American company in charge of its home market.</p><p>The companies did not purchase experimental drug candidates as they did last week when drugmakers, including Novo Nordisk and Novartis, invested in experimental drugs.</p><h2 class="st-heading-2">Viatris Buys A Pain Franchise</h2><p>Viatris (VTRS) agreed on Thursday to buy Pacira BioSciences (PCRX) for $1.65 billion in cash, or $36.50 a share. That was a premium of about 45% to Pacira’s last close.</p><p>Pacira sells Exparel, a long-acting numbing shot used after surgery, and Zilretta, an injection for knee arthritis. Pacira expects Exparel sales of $600 million to $620 million this year. Viatris, which is waiting on a U.S. decision for its own non-opioid pain drug, said the products fit its push into branded medicines and that it would try to sell them in more countries. The deal is expected to close by the end of 2026. Pacira shares closed Thursday at $36.39, up 44%.</p><h2 class="st-heading-2">GE Healthcare Buys The Delivery Network</h2><p>GE HealthCare (GEHC) agreed to pay $945 million in cash for Sofie Biosciences, a private U.S. firm that makes radioactive tracers for PET scans. Sofie runs 15 manufacturing sites and 21 cyclotrons. The tracers fade within hours, so the plant has to be near the hospital. GE also gets U.S. rights to FAPI-74, an experimental cancer-imaging agent it already controls outside the country. Sofie already makes GE’s heart-scan product Flyrcado. Closing is expected in the first half of 2027.</p><h2 class="st-heading-2">Two Biotechs License Out</h2><p>Biohaven (BHVN) licensed Asian rights to its antibody-clearing drugs to Japan’s Ono Pharmaceutical. The package is $80 million at signing and a further $20 million expected within about a year, plus royalties of roughly 20 percent on Ono’s sales in Japan and other Asian markets. Biohaven keeps the United States, Europe, and China. The lead drug, BHV-1300, is in a late-stage study for Graves’ disease.</p><p>Alector (ALEC) signed a separate license with Genentech, the U.S. unit of Roche (RHHBY). Alector gets $100 million upfront and could receive up to $1.17 billion more for AL-050, an experimental enzyme therapy aimed at Parkinson’s and other brain disorders. Genentech gained worldwide rights to develop the AL-050 program. The deal lands three months after GSK (GSK) walked away from an older Alector partnership.</p><h2 class="st-heading-2">How Did Retail Traders React?</h2><p>On Stocktwits, retail sentiment around VTRS and PCRX &nbsp;was in 'bullish' territory over the past 24 hours, while GEHC and BHVN stayed within the 'neutral' territory. Sentiment around ALEC stayed within the 'extremely bullish' territory.</p><p>While VTRS has gained 42% year-to-date, PCRX has added 40%, BHVN 7%, and ALEC 33%. Meanwhile, GEHC has fallen 20%.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/mrna-stock-sets-new-52-week-high-as-nasdaq-100-reentry-meets-nih-cancer-vaccine-push/cZxGGuoRBnj">MRNA Stock Sets New 52-Week High As Nasdaq-100 Reentry Meets NIH Cancer-Vaccine Push</a></p><p>For updates and corrections, email newsroom[at]stocktwits[dot]com</p>

Assortment of multi-colored pills, tablets, and capsules scattering on a vibrant blue surface representing healthcare and medicine. Source: Getty Images

Drugmakers this week did not purchase experimental drug candidates but invested in approved drugs and a factory that makes imaging agents. 

Current Price	$2.05
Prev Close	$2.15
Open	$2.17
Dividend Yield	0.00%
50-Day Moving Average	$2.08
Beta	1.77
Avg. Volume	6.84M
PE Ratio	-1.97

52-Week High	$2.76
52-Week Low	$1.09
Market Capitalization	$318.75M
EPS (Annual)	-$1.39
Price to Book	-24.08
Revenue Per Employee	$204,320.39

Feed

News

Sentiment

Earnings

Fundamentals

Info

ALEC Fundamentals